is there a doctor out there or analyst who knows what percentage of prescriptions for Byetta are estimated to be off-label for obesity or over-weight patients? Is AMLN going to file with the FDA for this application? What, if any, advantage does Byetta have over their obesity-specific drugs currently in the pipeline?
I am not a doctor but FWIW Byetta is the drug that Doctors are more comfortable with at this point in time.The black box on Symlin keeps them nervous. Neither is approved for obesity so I think they are trying B more than S even though trails show better weight loss with Symlin.The black box will be gone soon.IMO